|
Molecular sequencing and gene fusion detection in non-small cell lung cancer (NSCLC) patients: Impact of co-existing alterations. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Boehringer Ingelheim |
Consulting or Advisory Role - Boehringer Ingelheim |
|
|
Honoraria - Boehringer Ingelheim |
Consulting or Advisory Role - Boehringer Ingelheim |
|
|
Honoraria - Boehringer Ingelheim |
Consulting or Advisory Role - Boehringer Ingelheim |
|
|
Stock and Other Ownership Interests - Boehringer Ingelheim; Pfizer |
Honoraria - Boehringer Ingelheim |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma; Roche/Genentech |
|
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Merck; Sysmex |
Travel, Accommodations, Expenses - Sysmex |